Skip to main content

Table 3 Univariate and multivariate analysis between virological Failure and adequate virological response

From: Outcome of patients on second line antiretroviral therapy under programmatic condition in India

Characteristics Uni-variate p-value Multi-variate p-value
  Odds ratio (95 % CI)   Odds ratio (95 % CI)  
Age (years)
 >40 1.249 (0.496-3.147) 0.637   
 ≤40 1    
Sex
 Male 0.423 (0.161-1.112) 0.081   
 Female 1    
WHO Stage 1st line
 III + IV 1.038 (0.400-2.698) 0.938   
 I + II 1    
Tuberculosis 1st line
 Yes 2.327 (0.968-2.327) 0.059   
 No 1    
Adherence 1st line
 <95 % 2.600 (1.090-6.201) 0.031 1.918 (0.741-4.962) 0.180
 >95 % 1   1  
Weight (Kg) 1st line
 ≤45 1.215 (0.517-2.854) 0.655   
 >45 1    
CD4 count 1st line (/μL)
 <200 3.618 (1.455-8.998) 0.006 2.788 (1.045-7.439) 0.041
 >200 1   1  
Duration of Immunological failure (months)
 >12 0.542 (0.229-1.283) 0.164   
 <12 1    
Clinical failure
 Yes 5.253 (0.673-40.976) 0.114   
 No 1    
CD4 count less than baseline
 Yes 2.335 (0.949-5.749) 0.065   
 No 1    
50 % fall from peak CD4 count
 Yes 1.092 (0.339-3.519) 0.882   
 No 1    
CD4 count < 100/μL
 Yes 0.688 (0.297-1.593) 0.382   
 No 1    
CD4 count 2nd line (/μL)
 <200 3.275 (0.856-12.537) 0.083   
 >200 1    
WHO Stage 2nd line
 III + IV 1.287 (0.477-3.477) 0.618   
 I + II 1    
Weight (Kg) 2nd line
 ≤45 1.143 (0.492-2.653) 0.756   
 >45 1    
Viral Load 2nd Line (copies/ml)
 >177000 3.558 (1.399-9.050) 0.008 3.402 (1.272-9.097) 0.015
 ≤177000 1   1  
Tuberculosis 2nd line
 Yes 1.364 (0.455-4.090) 0.580   
 No 1    
Adherence 2nd line
 <95 % 2.870 (1.176-7.004) 0.021 2.788 (1.044-7.445) 0.041
 >95 % 1   1